SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

NDA submission with strong Phase 3 data de-risks encaleret's approval path for ADH1. Watch for FDA acceptance and priority review decision, which could accelerate timeline. Expansion into chronic hypoparathyroidism (RECLAIM-HP) represents a larger market opportunity. Monitor for any FDA advisory committee meeting or CRL risk.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.95
T+0 close · May 12, 2026 · via day close
Latest settled
+25.55%
T+60 · $82.80
Vs SPY
+21.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $65.95entry
  2. T+1 · 6mo ago +4.03%α +3.46% · $68.61
  3. T+5 · 6mo ago −0.96%α −1.03% · $65.32
  4. T+20 · 5mo ago +2.21%α +3.93% · $67.41
  5. T+60 · 3mo ago +25.55%α +21.17% · $82.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showing 76% of patients achieved target calcium levels vs 4% on standard of care (p<0.0001). If approved, encaleret would be the first approved therapy for ADH1, with a potential U.S. launch in early 2027 and an estimated diagnosed patient population of ~2,000 in the U.S.

Key Facts

  • NDA submitted to FDA for encaleret in autosomal dominant hypocalcemia type 1 (ADH1)
  • Phase 3 CALIBRATE trial met all primary and key secondary endpoints
  • 76% of encaleret patients achieved target serum and urine calcium vs 4% on conventional therapy (p<0.0001)
  • Encaleret restored endogenous PTH in 91.1% of patients vs 0% on standard of care at Week 24
  • No discontinuations in encaleret arm; favorable safety profile
  • Potential first approved therapy for ADH1; U.S. launch anticipated early 2027
  • Nearly 2,000 diagnosed ADH patients in U.S. since Oct 2023 based on claims data
  • MAA submission to EMA planned for H2 2026
  • Phase 2/3 pediatric study (CALIBRATE-PEDS) enrolling; Phase 3 chronic hypoparathyroidism study (RECLAIM-HP) planned for Summer 2026
  • Fast Track and Orphan Drug designations from FDA; Orphan in EU and Japan

Financial Impact

First-to-market therapy for ADH1 with ~2,000 diagnosed U.S. patients; potential expansion to chronic hypoparathyroidism (larger market). No revenue guidance provided.

revenuepipeline value

Risk Factors

  • FDA may not accept NDA or may issue Complete Response Letter
  • ADH1 is ultra-rare (~2,000 diagnosed patients) limiting peak revenue potential
  • Competition from existing calcium/vitamin D therapies and potential future entrants
  • Regulatory delays or additional clinical data requirements
  • Commercial execution risk in a rare disease with small prescriber base

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292712

Track record

38 reports on BBIO

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026